Bristol-Myers Squibb Co vs Honeywell International Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.82 (market cap $129.94B), while Honeywell International Inc trades at $234.55 (market cap $72.93B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | HON | |
|---|---|---|
Market Cap | $129.94B | $72.93B |
Sector | Health | Industrials |
52-Week High | $65.89 | $248.79 |
52-Week Low | $42.60 | $188.14 |
Enterprise Value | $163.92B | $97.73B |
Dividend Yield | 3.96% | 1.22% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Honeywell International Inc. (HON) trades at $232.35, down 4.36% amid disappointing growth guidance from a recent investor event. The stock exhibits bearish technical signals with support near $225, while fundamentals remain solid with a low P/E of 8.85 and strong profitability margins. Recent corporate actions include dividend payments and business divestitures, positioning the company as a focused automation play.
The outlook is mixed: attractive valuation and consistent earnings beats support upside toward the $320.54 consensus target, but near-term sentiment is pressured by growth concerns and technical weakness. Key risks include execution of the portfolio transformation and macroeconomic headwinds affecting industrial demand.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →